Holen Sie sich die Stockscreener-App
2.24
1.36%
0.03
Handel nachbörslich:
2.25
0.010
+0.45%
Goodrx Holdings Inc Aktie (GDRX) Neueste Nachrichten
Published on: 2026-03-12 03:47:43 - baoquankhu1.vn
GoodRx (NASDAQ:GDRX) Shares Down 6%Time to Sell? - MarketBeat
GoodRx Holdings, Inc. announced that consumers paying with cash through its platform can enjoy up to 85% discounts on medications at more than 70,000 pharmacies across the United States. - Bitget
GoodRx (GDRX) Partners with Viatris for Major Medication Discoun - GuruFocus
GoodRx offers up to 85% discount on Viatris drugs (GDRX) - Seeking Alpha
Lipitor and Viagra discounts: GoodRx deal cuts brand drugs to $0–$4 - Stock Titan
GoodRx: Losing Relevance With Consumers (Downgrade) (NASDAQ:GDRX) - Seeking Alpha
GoodRx (GDRX) Q4 2025 Earnings Call Transcript - AOL.com
Aug Technicals: How does GoodRx Holdings Inc perform in inflationary periods2025 Investor Takeaways & Verified Momentum Stock Ideas - baoquankhu1.vn
Aug Reactions: Is GoodRx Holdings Inc showing insider buyingMarket Movement Recap & Short-Term High Return Ideas - baoquankhu1.vn
GoodRx awards discretionary cash bonus to chief accounting officer - Investing.com UK
GoodRx awards discretionary cash bonus to chief accounting officer By Investing.com - Investing.com South Africa
GoodRx Awards Performance-Based Bonus to Chief Accounting Officer - TipRanks
GoodRx (GDRX) Board approves $72,918 bonus for Chief Accounting Officer - Stock Titan
U.S. medical discount service provider GoodRx Holdings, Inc. recently announced the launch of an innovative subsidy program for self-insured employers. - Bitget
GoodRx to expand employer-sponsored access to Zepbound® Kwikpen® - marketscreener.com
Obesity drug Zepbound now offered to workers at $449 through GoodRx - Stock Titan
GDRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
GDRX: Wells Fargo Maintains Rating, Lowers Price Target by 50% | - GuruFocus
Wells Fargo & Company Has Lowered Expectations for GoodRx (NASDAQ:GDRX) Stock Price - MarketBeat
GoodRx Holdings (GDRX) Analyst Rating Update: Citigroup Lowers P - GuruFocus
Citigroup Lowers GoodRx (NASDAQ:GDRX) Price Target to $3.50 - MarketBeat
GoodRx Holdings, Inc. (GDRX) Stock Analysis: A 51.74% Upside Potential Awaits Investors - DirectorsTalk Interviews
GDRX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
GoodRx (NASDAQ:GDRX) Trading Up 9.4%Should You Buy? - MarketBeat
The Goldman Sachs Group Lowers GoodRx (NASDAQ:GDRX) Price Target to $2.50 - MarketBeat
Goldman Sachs Lowers GoodRx Holdings (GDRX) Price Target to $2.5 - GuruFocus
GoodRx Earnings Call Marks Transitional Reset Year - TipRanks
GoodRx Announces Resignation of Board Member Dipanjan Deb - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: GoodRx Holdings (GDRX) and Vericel (VCEL) - The Globe and Mail
Assessing GoodRx Holdings (GDRX) Valuation After Employer Direct Launch And Post Earnings Analyst Shifts - simplywall.st
Why GoodRx (GDRX) Is Down 19.4% After Unveiling Employer Direct And 2026 Revenue Guidance - Yahoo Finance
GoodRx (GDRX) board member Dipanjan Deb steps down without dispute - Stock Titan
GoodRx Holdings, Inc.Class A Common Stock (NQ: GDRX - The Chronicle-Journal
GoodRx Holdings (GDRX) Analyst Rating and Price Target Update | - GuruFocus
GoodRx (NASDAQ:GDRX) Given New $3.00 Price Target at Mizuho - MarketBeat
Hims & Hers Expands Digital Health and Global Platform Strategy - TradingView
GoodRx 2026 Guidance Signals Material Reset, Morgan Stanley Says - marketscreener.com
UBS Lowers Price Target on GoodRx Holdings to $2 From $4, Maintains Neutral Rating - marketscreener.com
Raymond James cuts GoodRx stock price target on pharma headwinds By Investing.com - Investing.com Nigeria
Raymond James cuts GoodRx stock price target on pharma headwinds - Investing.com
JPMorgan Chase & Co. Reaffirms Neutral Rating for GoodRx (NASDAQ:GDRX) - MarketBeat
A Glimpse Into The Expert Outlook On GoodRx Holdings Through 4 Analysts - Benzinga
GoodRx Holdings (GDRX) Downgraded by JP Morgan to Neutral | GDRX Stock News - GuruFocus
JPMorgan Downgrades GoodRx to Neutral From Overweight - marketscreener.com
Morgan Stanley Cuts Price Target on GoodRx Holdings to $3 From $4, Keeps Equalweight Rating - marketscreener.com
GDRX: GoodRx drives ~$17B in annual consumer savings and achieves profitable growth with expanding partnerships - TradingView
GoodRx Holdings GDRX Margin Improvement Reinforces Bullish Profitability Narratives - simplywall.st
GoodRx Q4 2025 Earnings: Revenue Down, Future Guidance Below EstimatesNews and Statistics - IndexBox
GoodRx Holdings, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Leerink Maintains Outperform on GoodRx (GDRX) Feb 26, 2026 PT $3 - Meyka
JPMorgan Downgrades GoodRx Holdings Inc. (GDRX) to Neutral - StreetInsider
GoodRx Holdings Inc. (GDRX) PT Lowered to $1.90 at BofA Securities - StreetInsider
GoodRx Holdings Inc (GDRX) Q4 2025 Earnings Call Highlights: Pha - GuruFocus
GoodRx expects Pharma Direct revenue growth of at least 30% in 2026 amid shift to pharma manufacturer solutions - MSN
Leerink cuts GoodRx stock price target to $3 on weak guidance - Investing.com Nigeria
Leerink cuts GoodRx stock price target to $3 on weak guidance By Investing.com - Investing.com South Africa
GoodRx Holdings Inc. (GDRX) PT Lowered to $3 at Leerink Partners - StreetInsider
GoodRx (NASDAQ:GDRX) Sets New 52-Week LowHere's What Happened - MarketBeat
GDRX: Pharma Direct revenue surged 41% in 2025, driving growth amid evolving healthcare trends - TradingView
Earnings call transcript: GoodRx Q4 2025 revenue meets expectations amid strategic shifts - Investing.com
0.79%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):